Technical analysis of Surrozen, Inc. (SRZN): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Price Performance
| 1 month | -29.46% |
| 3 months | -27.18% |
| Year-to-date | -25.09% |
| 1 year | +46.58% |
| 3 years | +137.86% |
52-Week Range
| 52-week High | $35.00 |
| 52-week Low | $11.35 |
| Avg Volume (90d) | 182K |
Technical Indicators
| SMA 50 | $22.07 |
| SMA 200 | $24.24 |
| Beta | 0.52 |
| 30-day Volatility (annualised) | 67.4% |
| Price vs SMA 50 | -23.3% |
| Price vs SMA 200 | -30.2% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $14.00 | |
| 2025-11 | $16.58 | +18.4% |
| 2025-12 | $22.60 | +36.3% |
| 2026-01 | $21.55 | -4.6% |
| 2026-02 | $27.80 | +29.0% |
| 2026-03 | $29.13 | +4.8% |
| 2026-04 | $33.40 | +14.7% |
| 2026-05 | $26.21 | -21.5% |
| 2026-06 | $25.95 | -1.0% |
| 2026-07 | $22.21 | -14.4% |
| 2026-08 | $22.02 | -0.9% |
| 2026-09 | $16.93 | -23.1% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
Price
| Price | $16.93 |
| Market Cap | $127M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -0.90 |
| EV / EBITDA | -0.22 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -0.03 |
| Current Ratio | 12.14 |